FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis

[1]  R. del Campo,et al.  Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. , 2016, Journal of hepatology.

[2]  F. Tacke,et al.  In search of the magic bullet: can liver inflammation and fibrosis be reversed with medications? , 2015, Expert review of gastroenterology & hepatology.

[3]  K. Lindor,et al.  Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. , 2015, Gastroenterology.

[4]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[5]  T. Roskams,et al.  The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. , 2015, The American journal of pathology.

[6]  T. Roskams,et al.  Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats , 2014, Hepatology.

[7]  Frank Tacke,et al.  Macrophage heterogeneity in liver injury and fibrosis. , 2014, Journal of hepatology.

[8]  F. Schuit,et al.  Gene Expression Profiling of Early Hepatic Stellate Cell Activation Reveals a Role for Igfbp3 in Cell Migration , 2013, PloS one.

[9]  R. Schwabe,et al.  Fate-tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its etiology , 2013, Nature Communications.

[10]  R. Schwabe,et al.  Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice , 2013, Hepatology.

[11]  T. Luedde,et al.  Experimental liver fibrosis research: update on animal models, legal issues and translational aspects , 2013, Fibrogenesis & tissue repair.

[12]  T. Luedde,et al.  Chemokine Receptor CXCR6-Dependent Hepatic NK T Cell Accumulation Promotes Inflammation and Liver Fibrosis , 2013, The Journal of Immunology.

[13]  M. Odenthal,et al.  Class II HDAC Inhibition Hampers Hepatic Stellate Cell Activation by Induction of MicroRNA-29 , 2013, PloS one.

[14]  S. Malik,et al.  Quercetin suppresses inflammation by reducing ERK1/2 phosphorylation and NF kappa B activation in Leptin-induced Human Umbilical Vein Endothelial Cells (HUVECs) , 2013, BMC Research Notes.

[15]  T. Sauerbruch,et al.  HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. , 2012, Journal of hepatology.

[16]  S. Coulon,et al.  Leptin-mediated reactive oxygen species production does not significantly affect primary mouse hepatocyte functions in vitro , 2012, European journal of gastroenterology & hepatology.

[17]  F. Lammert,et al.  Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats , 2012, Laboratory Investigation.

[18]  L. Adorini,et al.  Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. , 2012, Drug discovery today.

[19]  F. Nevens,et al.  Bench-to-beside review: Acute-on-chronic liver failure - linking the gut, liver and systemic circulation , 2011, Critical care.

[20]  Peter D Siersema,et al.  Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-κB signaling in the intestine. , 2011, Biochimica et biophysica acta.

[21]  G. Guo,et al.  Tissue-specific function of farnesoid X receptor in liver and intestine. , 2011, Pharmacological research.

[22]  P. Siersema,et al.  Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease , 2011, Gut.

[23]  F. Lammert,et al.  Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. , 2010, Journal of hepatology.

[24]  Scott L. Friedman,et al.  Evolving challenges in hepatic fibrosis , 2010, Nature Reviews Gastroenterology &Hepatology.

[25]  Jun-ji Ma,et al.  New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. , 2010, Journal of hepatology.

[26]  V. Rogiers,et al.  Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo , 2010, Hepatology.

[27]  K. Zatloukal,et al.  Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. , 2009, The American journal of pathology.

[28]  E. Distrutti,et al.  The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis1 , 2009, The Journal of Immunology.

[29]  R. Schwabe,et al.  CCR2 promotes hepatic fibrosis in mice , 2009, Hepatology.

[30]  B. M. Forman,et al.  Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response , 2008, Hepatology.

[31]  S. Friedman,et al.  Mechanisms of hepatic fibrogenesis. , 2008, Gastroenterology.

[32]  R. Hay,et al.  NF-kappaB is a critical regulator of the survival of rodent and human hepatic myofibroblasts. , 2008, Journal of hepatology.

[33]  S. Dooley,et al.  Profibrogenic transforming growth factor‐β/activin receptor–like kinase 5 signaling via connective tissue growth factor expression in hepatocytes , 2007, Hepatology.

[34]  A. Elsharkawy,et al.  Nuclear factor‐κB and the hepatic inflammation‐fibrosis‐cancer axis , 2007 .

[35]  Didier Merlin,et al.  Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. , 2007, Cancer research.

[36]  F. Nevens,et al.  Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. , 2007, Gastroenterology.

[37]  Y. Inagaki,et al.  Emerging insights into Transforming growth factor β Smad signal in hepatic fibrogenesis , 2007, Gut.

[38]  Yun Yen,et al.  Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. , 2007, Cancer research.

[39]  He-sheng Luo,et al.  Reversal Effect of Thalidomide on Established Hepatic Cirrhosis in Rats via Inhibition of Nuclear Factor-κB/Inhibitor of Nuclear Factor-κB Pathway , 2007 .

[40]  A. Elsharkawy,et al.  Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. , 2007, Hepatology.

[41]  He-sheng Luo,et al.  Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. , 2007, Archives of medical research.

[42]  T. Roskams,et al.  A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited , 2006, European journal of clinical investigation.

[43]  F. Nevens,et al.  Portal hypertension: from pathophysiology to clinical practice , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[44]  C. J. Marek,et al.  Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. , 2005, Gastroenterology.

[45]  S. Friedman,et al.  Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis , 2004, Gut.

[46]  A. Morelli,et al.  The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. , 2004, Gastroenterology.

[47]  T. Willson,et al.  6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.

[48]  J. Iredale,et al.  Inhibition of Apoptosis of Activated Hepatic Stellate Cells by Timp-1 is Mediated via Effects on Mmp Inhibition: Implications for Reversibility of Liver Fibrosis , 2002 .

[49]  John P. Iredale,et al.  Inhibition of Apoptosis of Activated Hepatic Stellate Cells by Tissue Inhibitor of Metalloproteinase-1 Is Mediated via Effects on Matrix Metalloproteinase Inhibition , 2002, The Journal of Biological Chemistry.

[50]  T. Roskams,et al.  Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. , 2001, Journal of hepatology.

[51]  P. Bioulac-Sage,et al.  [Mechanisms of hepatic fibrogenesis]. , 2002, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[52]  N. Fausto,et al.  Tumor Necrosis Factor Induces DNA Replication in Hepatic Cells through Nuclear Factor {{kappa}}B Activation , 1999 .

[53]  N. Fausto,et al.  Tumor necrosis factor induces DNA replication in hepatic cells through nuclear factor kappaB activation. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[54]  S. Harrison,et al.  Structure of an IκBα/NF-κB Complex , 1998, Cell.

[55]  S. Harrison,et al.  Structure of an IkappaBalpha/NF-kappaB complex. , 1998, Cell.

[56]  J. Iredale,et al.  Pathogenesis of liver fibrosis. , 1997, Clinical science.

[57]  H. Herbst,et al.  Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. , 1996, The American journal of pathology.